title
stringlengths 2
458
| image
stringlengths 0
731
⌀ | text
stringlengths 0
10k
| url
stringlengths 23
416
| type
stringclasses 2
values | context_id
stringlengths 1
8
⌀ | source
stringlengths 2
42
| date
stringlengths 19
25
|
|---|---|---|---|---|---|---|---|
Becton Dickinson (BDX) Crossed Above the 20-Day Moving Average: What That Means for Investors
|
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
|
https://www.zacks.com/stock/news/1872610/becton-dickinson-bdx-crossed-above-the-20-day-moving-average-what-that-means-for-investors
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2022-02-24 11:35:52
|
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
|
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
|
https://www.zacks.com/stock/news/1871917/here-s-why-you-should-retain-bd-bdx-stock-in-your-portfolio
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2022-02-23 13:06:33
|
|
Becton Dickinson (BDX) Crossed Above the 20-Day Moving Average: What That Means for Investors
|
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
|
https://www.zacks.com/stock/news/1862788/becton-dickinson-bdx-crossed-above-the-20-day-moving-average-what-that-means-for-investors
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2022-02-04 11:29:21
|
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2022 Results - Earnings Call Transcript
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2022 Results - Earnings Call Transcript
|
https://seekingalpha.com/article/4484045-becton-dickinson-and-company-bdx-ceo-thomas-polen-on-q1-2022-results-earnings-call-transcript
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2022-02-03 13:33:16
|
|
Becton Dickinson Q1 Earnings Top Estimates, Raises FY22 Guidance On Higher COVID-19 Related Sales
|
Becton Dickinson and Co BDX reported Q1 FY22 revenues of $4.9 billion, down 6% Y/Y (-5.9% on a currency-neutral basis), better than the consensus of $4.76 billion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
|
https://www.benzinga.com/news/earnings/22/02/25394543/becton-dickinson-q1-earnings-top-estimates-raises-fy22-guidance-on-higher-covid-19-related-sales
|
strategic_field
|
BDXA
|
Benzinga
|
2022-02-03 11:27:06
|
|
Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates
|
Becton Dickinson (BDX) delivered earnings and revenue surprises of 27.27% and 4.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
|
https://www.zacks.com/stock/news/1861844/becton-dickinson-bdx-surpasses-q1-earnings-and-revenue-estimates
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2022-02-03 09:14:13
|
|
Should You Buy Becton, Dickinson and Company (BDX) Ahead of Earnings?
|
Becton, Dickinson and Company (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
|
https://www.zacks.com/stock/news/1861271/should-you-buy-becton-dickinson-and-company-bdx-ahead-of-earnings
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2022-02-02 10:46:16
|
|
Becton Dickinson Strengthens Post-Treatment Monitoring For Blood Cancers With Cytognos Acquisition
|
Becton, Dickinson and Co (NYSE: BDX) has acquired Cytognos, a unit of Vitro SA, a Spanish diagnostics company that develops, produces, and sells fully integrated reagents, hardware, and software platforms. Deal terms were not disclosed.
|
https://www.benzinga.com/m-a/22/02/25337281/becton-dickinson-strengthens-post-treatment-monitoring-for-blood-cancers-with-cytognos-acquisition
|
strategic_field
|
BDXA
|
Benzinga
|
2022-02-01 10:02:43
|
|
Becton Dickinson (BDX) Expected to Beat Earnings Estimates: Should You Buy?
|
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
|
https://www.zacks.com/stock/news/1858599/becton-dickinson-bdx-expected-to-beat-earnings-estimates-should-you-buy
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2022-01-27 16:10:13
|
|
Why the Earnings Surprise Streak Could Continue for Becton Dickinson (BDX)
|
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
|
https://www.zacks.com/stock/news/1852278/why-the-earnings-surprise-streak-could-continue-for-becton-dickinson-bdx
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2022-01-14 13:53:10
|
|
Becton, Dickinson And Company: Stable, Profitable, And Offering At-Home COVID-19 Testing
|
Beckton, Dickinson and Company is a Profitable Dividend Aristocrat that generates tons of cash.
|
https://seekingalpha.com/article/4479303-becton-dickinson-and-company-stable-profitable-and-offering-home-covidminus-19-testing
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2022-01-12 14:56:38
|
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
|
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic buyouts.
|
https://www.zacks.com/stock/news/1850492/here-s-why-you-should-retain-bd-bdx-stock-in-your-portfolio
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2022-01-11 13:50:10
|
|
BD (BDX) Partners With Retailers for At-Home COVID-19 Test
|
BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.
|
https://www.zacks.com/stock/news/1843696/bd-bdx-partners-with-retailers-for-at-home-covid-19-test
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-12-27 09:57:22
|
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
|
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
|
https://www.zacks.com/stock/news/1836901/here-s-why-you-should-retain-bd-bdx-stock-in-your-portfolio
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-12-08 12:07:09
|
|
Becton Dickinson to name diabetes care spinoff 'embecta'
|
Becton Dickinson & Co. BDX, +0.90% said Monday that the spinoff of its diabetes care business will be named "embecta." The previously announced spinoff, into an independent publicly traded company, is expected to be completed in the second quarter of 2022.
|
https://www.marketwatch.com/story/becton-dickinson-to-name-diabetes-care-spinoff-embecta-2021-12-06
|
strategic_field
|
BDXA
|
Market Watch
|
2021-12-06 07:05:07
|
|
Becton, Dickinson & Co. Is Trading at a Discount
|
Shares of Becton, Dickinson and Co. ( BDX , Financial) reported earnings results earlier this month that came in above Wall Street analysts' estimates. Covid-19 remains a tailwind to the company's business, but the core segments also performed well.
|
https://www.gurufocus.com/news/1583735/becton-dickinson--co-is-trading-at-a-discount
|
strategic_field
|
BDXA
|
GuruFocus
|
2021-11-29 12:36:34
|
|
Rapid Covid-19 tests in high demand ahead of Thanksgiving
|
https://cdn.snapi.dev/images/v1/d/d/ddik223-1121402.
|
CNBC's Meg Tirrell joins 'Squawk Box' to report on the increased demand for Covid-19 tests ahead of the Thanksgiving holiday.
|
https://www.youtube.com/watch?v=RzMzxXjwJmg&ab_channel=CNBCTelevision
|
strategic_field
|
BDXA
|
CNBC Television
|
2021-11-23 09:31:00
|
Becton, Dickinson Is A Strong Buy At $250
|
Becton, Dickinson Is A Strong Buy At $250
|
https://seekingalpha.com/article/4470609-becton-dickinson-is-a-strong-buy-at-250
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2021-11-18 15:04:08
|
|
Qiagen, Becton Dickinson Settle Patent Infringement Lawsuit For $53M
|
Qiagen N.V. (NYSE: QGEN) settled with Becton Dickinson & Co (NYSE: BDX) a patent infringement lawsuit related to Qiagen's NeuMoDx 96 and NeuMoDx 288 clinical PCR systems.
|
https://www.benzinga.com/news/21/11/23947322/qiagen-becton-dickinson-settle-patent-infringement-lawsuit-for-53m
|
strategic_field
|
BDXA
|
Benzinga
|
2021-11-08 06:05:19
|
|
Becton, Dickinson and Company's (BDX) CEO Tom Polen on Q4 2021 Results - Earnings Call Transcript
|
Becton, Dickinson and Company's (BDX) CEO Tom Polen on Q4 2021 Results - Earnings Call Transcript
|
https://seekingalpha.com/article/4465531-becton-dickinson-and-companys-bdx-ceo-tom-polen-on-q4-2021-results-earnings-call-transcript
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2021-11-04 13:46:10
|
|
Becton Dickinson (BDX) Q4 Earnings and Revenues Beat Estimates
|
Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.58% and 4.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
|
https://www.zacks.com/stock/news/1823324/becton-dickinson-bdx-q4-earnings-and-revenues-beat-estimates
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-11-04 09:11:39
|
|
Becton Dickinson Starts Selling New At-Home Rapid COVID-19 Tests
|
Becton Dickinson and Co (NYSE: BDX) has partnered with Amazon.com Inc (NASDAQ: AMZN) to begin shipment of a new at-home rapid COVID-19 test that can confirm results using an entirely automated smartphone app. The BD Veritor At-Home COVID-19 Test, which U.S. regulators authorized in August, also automatically reports results to federal and state public health authorities.
|
https://www.benzinga.com/news/21/10/23558178/becton-dickinson-starts-selling-new-at-home-rapid-covid-19-tests
|
strategic_field
|
BDXA
|
Benzinga
|
2021-10-26 16:46:58
|
|
Can Becton Dickinson (BDX) Keep the Earnings Surprise Streak Alive?
|
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
|
https://www.zacks.com/stock/news/1816828/can-becton-dickinson-bdx-keep-the-earnings-surprise-streak-alive
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-10-26 13:25:13
|
|
Bear Of The Day: Becton, Dickinson and Co (BDX)
|
Despite a beating the number in the most recent report, this stock has fallen to the lowest Zacks Rank
|
https://www.zacks.com/commentary/1804932/bear-of-the-day-becton-dickinson-and-co-bdx
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-10-05 20:50:47
|
|
Becton Dickinson CEO on first Covid smartphone test and how it works
|
Thomas Polen, Becton Dickenson CEO, joins Closing Bell to talk about his company's smartphone Covid test.
|
https://www.youtube.com/watch?v=PIuHsHzS2qM
|
strategic_field
|
BDXA
|
CNBC Television
|
2021-09-10 16:03:38
|
|
Why Biden's Action Plan Is Bullish For COVID-19 Testing Stocks
|
On Thursday, President Joe Biden revealed his new COVID-19 action plan, which includes $2 billion in government spending on 280 million rapid point of care and at-home COVID-19 tests. On Friday, Bank of America analyst Bob Hopkins said Biden's new plan is good news for test manufacturers, including Becton Dickinson and Co (NYSE:BDX) and Abbott Laboratories (NYSE:ABT).
|
https://www.benzinga.com/analyst-ratings/analyst-color/21/09/22885309/why-bidens-action-plan-is-bullish-for-covid-19-testing-stocks
|
strategic_field
|
BDXA
|
Benzinga
|
2021-09-10 11:56:11
|
|
Becton, Dickinson And Company: One Of The Best Dividend SWANs You Can Buy Today
|
Becton, Dickinson And Company: One Of The Best Dividend SWANs You Can Buy Today
|
https://seekingalpha.com/article/4454439-becton-dickinson-one-of-the-best-dividend-swans-you-can-buy-today
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2021-09-10 02:00:06
|
|
Notable Becton Dickinson Insider Trades $5.72 Million In Company Stock
|
James Lim, Executive Vice President at Becton, Dickinson (NYSE:BDX), made a large buy and sell of company shares on September 3, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that James Lim purchased 14,584 Becton, Dickinson shares at a price of $134.73 per share for a total of $1,964,902 on September 3.
|
https://www.benzinga.com/news/21/09/22831986/notable-becton-dickinson-insider-trades-5-72-million-in-company-stock
|
strategic_field
|
BDXA
|
Benzinga
|
2021-09-07 14:14:26
|
|
BD (BDX) Veritor At-Home COVID-19 Test Receives EUA From FDA
|
EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.
|
https://www.zacks.com/stock/news/1787374/bd-bdx-veritor-at-home-covid-19-test-receives-eua-from-fda
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-08-26 13:01:14
|
|
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
|
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.
|
https://www.zacks.com/stock/news/1787320/here-s-why-you-should-retain-bd-bdx-stock-in-your-portfolio
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-08-26 12:14:16
|
|
BD Locks FDA Emergency Use Nod For At-Home COVID-19 Antigen Test
|
The FDA has issued an Emergency Use Authorization (EUA) for Becton Dickinson and Co's (NYSE: BDX) BD Veritor At-Home COVID-19 Test. Also Read: BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV
|
https://www.benzinga.com/general/biotech/21/08/22671766/bd-locks-fda-emergency-use-nod-for-at-home-covid-19-antigen-test
|
strategic_field
|
BDXA
|
Benzinga
|
2021-08-26 09:02:30
|
|
BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV
|
Becton Dickinson and Co (NYSE: BDX) has received FDA approval for its automated, sample-to-answer, high-throughput BD Cor system along with the BD Onclarity HPV Assay for extended genotyping of human papillomavirus (HPV). The modular and scalable BD Cor includes an automated sample preparation system, BD Cor PX, and an instrument that automates the BD Onclarity HPV assay, BD Cor GX.
|
https://www.benzinga.com/news/21/08/22661620/bds-automated-molecular-diagnostics-platform-wins-fda-approval-initial-test-for-hpv
|
strategic_field
|
BDXA
|
Benzinga
|
2021-08-25 13:46:15
|
|
JPMorgan Downgrades Becton Dickinson On Muffled FY22 Outlook
|
JPMorgan downgraded Becton Dickinson and Co (NYSE:BDX) to Neutral from Overweight with a price target of $265, down from $280. While Becton reported better than expected top and bottom-line Q3 results, analyst Robert Marcus tells investors that this was overshadowed by the company's "muted" Q4 and FY22 outlook.
|
https://www.benzinga.com/analyst-ratings/analyst-color/21/08/22379483/jpmorgan-downgrades-becton-dickinson-on-muffled-fy22-outlook
|
strategic_field
|
BDXA
|
Benzinga
|
2021-08-06 16:15:07
|
|
Becton Dickinson and Company (BDX) CEO Tom Polen on Q3 2021 Results - Earnings Call Transcript
|
Becton Dickinson and Company (BDX) CEO Tom Polen on Q3 2021 Results - Earnings Call Transcript
|
https://seekingalpha.com/article/4445472-becton-dickinson-and-company-bdx-ceo-tom-polen-on-q3-2021-results-earnings-call-transcript
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2021-08-05 13:10:04
|
|
Becton Dickinson (BDX) Q3 Earnings and Revenues Surpass Estimates
|
Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.38% and 8.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
|
https://www.zacks.com/stock/news/1774897/becton-dickinson-bdx-q3-earnings-and-revenues-surpass-estimates
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-08-05 09:09:30
|
|
Becton, Dickinson: Q3 Earnings Insights
|
Shares of Becton, Dickinson (NYSE:BDX) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 24.55% year over year to $2.74, which beat the estimate of $2.44.
|
https://www.benzinga.com/news/earnings/21/08/22346240/becton-dickinson-q3-earnings-insights
|
strategic_field
|
BDXA
|
Benzinga
|
2021-08-05 08:00:44
|
|
BD's (BDX) Rapid COVID-19 Test for US Olympic Trial Swimmers
|
BD (BDX) to provide rapid antigen testing for COVID-19 at the U.S. Olympic Team Trials and other competitive swimming events on behalf of USA Swimming.
|
https://www.zacks.com/stock/news/1716503/bds-bdx-rapid-covid-19-test-for-us-olympic-trial-swimmers
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-06-16 07:31:07
|
|
Matrix Asset's David Katz makes the case for Amgen, Viacom and Verizon
|
David Katz, Matrix Asset Advisors chief investment officer, and Jerry Castellini, CastleArk Management chief investment officer, join 'The Exchange' to discuss their market outlook as the economy reopens and the names they think will have value in this market environment. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis.
|
https://www.youtube.com/watch?v=nb0xEn06YJw
|
strategic_field
|
BDXA
|
CNBC Television
|
2021-05-27 17:07:36
|
|
Becton Dickinson To Build Fourth Facility In Spain To Expand Pre-Filled Drug Delivery Business
|
Becton Dickinson and Co (NYSE: BDX) will build a €165 million ($200 million) high-tech manufacturing facility in Zaragoza, Spain, that will create up to 600 jobs by 2030. BD plans to begin constructing the new plant in late 2021, and the new facility will be the fourth manufacturing plant for BD in Spain.
|
https://www.benzinga.com/news/21/05/21170666/becton-dickinson-to-build-fourth-facility-in-spain-to-expand-pre-filled-drug-delivery-business
|
strategic_field
|
BDXA
|
Benzinga
|
2021-05-18 06:51:11
|
|
Becton Dickinson To Spin Diabetes Care Unit In 2022
|
https://cdn.snapi.dev/images/v1/f/8/f8ii222-817841.
|
, a leading global medical technology company, announced that its Board of Directors have unanimously authorized management to go ahead with a plan to spinoff the Diabetes Care business into an independent, publicly traded company (“NewCo”).
|
https://www.forbes.com/sites/joecornell/2021/05/11/becton-dickinson-to-spin-diabetes-care-unit-in-2022/
|
strategic_field
|
BDXA
|
Forbes
|
2021-05-11 13:38:06
|
Becton, Dickinson & Co. Continues to Shine
|
Becton, Dickinson & Co. ( BDX , Financial) delivered another strong top and bottom-line beat when it reported earnings results last week.
|
https://www.gurufocus.com/news/1423078/becton-dickinson--co-continues-to-shine
|
strategic_field
|
BDXA
|
GuruFocus
|
2021-05-11 12:11:46
|
|
Syringe maker Becton, Dickinson CEO on the Covid supply chain
|
CNBC's "Power Lunch" team discusses syringe supply and the Covid supply chain with Becton, Dickinson CEO Tom Polen.
|
https://www.youtube.com/watch?v=f66gJaj2RKc
|
strategic_field
|
BDXA
|
CNBC Television
|
2021-05-06 15:32:28
|
|
Becton, Dickinson and Company (BDX) CEO Tom Polen on Q2 2021 Results - Earnings Call Transcript
|
Becton, Dickinson and Company (BDX) CEO Tom Polen on Q2 2021 Results - Earnings Call Transcript
|
https://seekingalpha.com/article/4425183-becton-dickinson-and-company-bdx-ceo-tom-polen-on-q2-2021-results-earnings-call-transcript
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2021-05-06 14:28:06
|
|
Becton Dickinson (BDX) Earnings Surpass Estimates in Q2
|
Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.
|
https://www.zacks.com/stock/news/1511028/becton-dickinson-bdx-earnings-surpass-estimates-in-q2
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-05-06 13:31:12
|
|
Becton Dickinson To Spin-Off Diabetes Care Business: Highlights
|
While reporting financial results for the second fiscal quarter of the year, during which revenues grew more than 15% to $4.9 billion, Becton Dickinson and Co (NYSE: BDX) also laid out its plans to spin off its diabetes-focused segment. Split Highlights: The split is expected to be completed in the first half of 2022, after which the segment will become a completely separate, publicly-traded company, tentatively dubbed “NewCo.”
|
https://www.benzinga.com/news/earnings/21/05/20993478/becton-dickinson-to-spin-off-diabetes-care-business-highlights
|
strategic_field
|
BDXA
|
Benzinga
|
2021-05-06 12:53:50
|
|
Becton Dickinson (BDX) Tops Q2 Earnings and Revenue Estimates
|
Becton Dickinson (BDX) delivered earnings and revenue surprises of 4.93% and 1.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
|
https://www.zacks.com/stock/news/1509300/becton-dickinson-bdx-tops-q2-earnings-and-revenue-estimates
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-05-06 08:16:27
|
|
Becton Dickinson beats profit expectations, plans to spin off Diabetes Care business
|
Becton Dickinson & Co. reported Thursday fiscal second-quarter profit and sales that rose above expectations, boosted by $480 million in COVID-19 testing sales, and announced plans to separate its Diabetes Care business into an independent publicly traded company. The medical technology company's stock was still inactive in premarket trading.
|
https://www.marketwatch.com/story/becton-dickinson-beats-profit-expectations-plans-to-spin-off-diabetes-care-business-2021-05-06
|
strategic_field
|
BDXA
|
Market Watch
|
2021-05-06 06:15:54
|
|
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
|
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
|
https://www.zacks.com/stock/news/1420485/will-becton-dickinson-bdx-beat-estimates-again-in-its-next-earnings-report
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-04-19 13:09:52
|
|
Becton, Dickinson - Three Reasons It Is A Buy
|
https://cdn.snapi.dev/images/v1/d/d/ddpl222-772680.
|
Becton, Dickinson is a market leader in multiple medical supply, laboratory, and diagnostic product categories. The company has deleveraged after two major acquisitions and the leverage ratio is now near 2.5X.
|
https://seekingalpha.com/article/4419800-becton-dickinson-three-reasons-is-buy
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2021-04-19 11:38:20
|
BD (BDX) Receives FDA EUA for Combination Rapid Antigen Test
|
BD (BDX) gets FDA EUA for new rapid, antigen test, which can distinguish between COVID-19, influenza A and influenza B in a single test.
|
https://www.zacks.com/stock/news/1324658/bd-bdx-receives-fda-eua-for-combination-rapid-antigen-test
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-03-31 13:38:22
|
|
BD gets FDA authorization for test that can detect COVID-19 and the flu
|
Becton, Dickinson & Co. said it received emergency authorization from the Food and Drug Administration for a rapid, antigen test that can detect SARS-CoV-2 and two types of influenza. The test, which runs on the company's BD Veritor System, takes about 15 minutes to produce results and is expected to be available this summer.
|
https://www.marketwatch.com/story/bd-gets-fda-authorization-for-test-that-can-detect-covid-19-and-the-flu-2021-03-30
|
strategic_field
|
BDXA
|
Market Watch
|
2021-03-30 07:24:10
|
|
Becton, Dickinson And Company: Expect More Cash To Head To Shareholders
|
Becton, Dickinson and Company is a Dividend Champion with 49 consecutive years of dividend. Shares currently yield 1.35%.
|
https://seekingalpha.com/article/4412609-becton-dickinson-company-expect-cash-to-head-to-shareholders
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2021-03-09 16:28:51
|
|
Becton, Dickinson & Co.: Ride the Covid-19 Tailwinds
|
Leading medical device manufacturer Becton, Dickinson & Co. (NYSE:BDX), or BD, recently reported earnings results that showed the company greatly benefited from Covid-19-related sales. BD provides the testing kits and vaccine injection devices being used to combat the virus.
|
https://www.gurufocus.com/news/1370399/becton-dickinson--co-ride-the-covid19-tailwinds
|
strategic_field
|
BDXA
|
GuruFocus
|
2021-02-25 14:57:27
|
|
BD (BDX), Scanwell Health Collaborate on At-Home Coronavirus Test
|
BD (BDX) plans to develop a lateral flow antigen test and pair it with the Scanwell Health mobile app via the latest partnership.
|
https://www.zacks.com/stock/news/1267948/bd-bdx-scanwell-health-collaborate-on-at-home-coronavirus-test
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-02-23 09:52:13
|
|
BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test
|
BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.
|
https://www.zacks.com/stock/news/1263857/bd-bdx-gets-eua-ce-mark-for-new-molecular-diagnostic-test
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-02-16 11:23:09
|
|
Becton Dickinson Lauded by Frost & Sullivan for Enhancing Patient Experience with Its BD Intevia™ Autoinjector
|
The solution leverages a modular platform technology that allows rapid customization, optimizing time and cost for pharma companies SANTA CLARA, Calif., Feb. 16, 2021 /PRNewswire/ -- Based on its recent analysis of the global autoinjector drug delivery market, Frost & Sullivan recognizes...
|
https://www.prnewswire.com/news-releases/becton-dickinson-lauded-by-frost--sullivan-for-enhancing-patient-experience-with-its-bd-intevia-autoinjector-301227880.html
|
strategic_field
|
BDXA
|
PRNewsWire
|
2021-02-16 05:00:00
|
|
Becton, Dickinson's COVID-19/Influenza Combo Molecular Assay Wins FDA Emergency Use Nod
|
The FDA has granted Emergency Use Authorization (EUA) to Becton Dickinson and Co's (NYSE: BDX) new molecular test for both SARS-CoV-2 and Influenza A+B. The new test has also received a CE mark in Europe.
|
https://www.benzinga.com/general/biotech/21/02/19635239/becton-dickinsons-covid-19influenza-combo-molecular-assay-wins-fda-emergency-use-nod
|
strategic_field
|
BDXA
|
Benzinga
|
2021-02-12 08:43:45
|
|
Becton Dickinson plans dual dollar/euro bond offerings to repay debt
|
Medical technology company Becton Dickinson and Co. said Wednesday it is planning a dual-tranche bond offering in dollars and euros to raise the funds to repay outstanding debt. In a regulatory filing, Becton said it will offer $1 billion of 1.957% 10-year bonds and 600 million euros of 1.213% 15-year bonds.
|
https://www.marketwatch.com/story/becton-dickinson-plans-dual-dollareuro-bond-offerings-to-repay-debt-2021-02-10
|
strategic_field
|
BDXA
|
Market Watch
|
2021-02-10 06:49:04
|
|
Covid-19 testing drives Becton Dickinson Q1 revenue growth
|
Medical devices company Becton Dickinson beat the top and bottom line in its first-quarter results. Covid-19 testing helped drive its revenue growth to $867 million.
|
https://www.youtube.com/watch?v=ndq_g7bJ1FY
|
strategic_field
|
BDXA
|
CNBC Television
|
2021-02-05 16:18:34
|
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2021 Results - Earnings Call Transcript
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2021 Results - Earnings Call Transcript
|
https://seekingalpha.com/article/4403452-becton-dickinson-and-company-bdx-ceo-thomas-polen-on-q1-2021-results-earnings-call-transcript
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2021-02-04 13:49:04
|
|
Becton Dickinson (BDX) Earnings Surpass Estimates in Q1
|
Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal first quarter.
|
https://www.zacks.com/stock/news/1257753/becton-dickinson-bdx-earnings-surpass-estimates-in-q1
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-02-04 13:36:12
|
|
Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates
|
Becton Dickinson (BDX) delivered earnings and revenue surprises of 44.90% and 0.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
|
https://www.zacks.com/stock/news/1257320/becton-dickinson-bdx-surpasses-q1-earnings-and-revenue-estimates
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-02-04 08:19:43
|
|
Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Q1 Release
|
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
|
https://www.zacks.com/stock/news/1253633/becton-dickinson-bdx-earnings-expected-to-grow-what-to-know-ahead-of-q1-release
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-01-28 13:32:45
|
|
Becton, Dickinson's (BDX) Shares March Higher, Can It Continue?
|
As of late, it has definitely been a great time to be an investor in Becton, Dickinson and Company (BDX).
|
https://www.zacks.com/stock/news/1249881/becton-dickinsons-bdx-shares-march-higher-can-it-continue
|
strategic_field
|
BDXA
|
Zacks Investment Research
|
2021-01-21 11:17:25
|
|
Final Trades: Zynga, Becton Dickinson & more
|
https://cdn.snapi.dev/images/v1/d/d/ddostfi2.
|
The "Halftime Report" investment committee give their top picks to watch for the second half.
|
https://www.youtube.com/watch?v=SR7odyA5hOw
|
strategic_field
|
BDXA
|
CNBC Television
|
2021-01-12 13:51:57
|
Becton Dickinson stock rallies after upbeat revenue outlook
|
Shares of Becton Dickinson & Co. rallied 2.3% in premarket trading Tuesday, after the medical technology company provided an upbeat outlook for its first quarter. For the quarter ended Dec. 31, the company expects to report revenue of $5.3 billion, up 26% from a year ago and above the FactSet consensus of $4.7 billion.
|
https://www.marketwatch.com/story/becton-dickinson-stock-rallies-after-upbeat-revenue-outlook-2021-01-12
|
strategic_field
|
BDXA
|
Market Watch
|
2021-01-12 06:40:32
|
|
Becton, Dickinson and Co.: A Fair Value Report
|
Are investors getting a shot in the arm or backing into a needle?
|
https://www.gurufocus.com/news/1321954/becton-dickinson-and-co-a-fair-value-report
|
strategic_field
|
BDXA
|
GuruFocus
|
2021-01-03 17:05:13
|
|
Becton, Dickinson & Co. Is a Highly Profitable, Recession-Proof Company
|
The health care sector is considered a defensive sector as people will seek out treatment for illness and aliments regardless of the status of the economy. Many companies in this sector literally provide products that consumers cannot live without.
|
https://www.gurufocus.com/news/1309357/becton-dickinson--co-is-a-highly-profitable-recessionproof-company
|
strategic_field
|
BDXA
|
GuruFocus
|
2020-12-11 14:37:12
|
|
Becton Dickinson Expects Covid Testing Sales to Hit $1.5 Billion
|
When it comes to Covid-19, Becton, Dickinson and Co. (NYSE:BDX) hasn't gained the attention of vaccine developers like Pfizer Inc. (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ), nor those companies with treatments like Gilead Sciences Inc. (NASDAQ:GILD). But the New Jersey-based medical device company has hardly been sitting on the sidelines.
|
https://www.gurufocus.com/news/1308647/becton-dickinson-expects-covid-testing-sales-to-hit-15-billion
|
strategic_field
|
BDXA
|
GuruFocus
|
2020-12-10 18:22:10
|
|
Becton Dickinson to invest $1.2 billion to expand pre-fillable syringe manufacturing capacity for COVID vaccination
|
Becton Dickinson & Co. said Wednesday it is planning to invest about $1.2 billion in pre-fillable syringe manufacturing capacity over the next four years. The Franklin Lakes, N.J.
|
https://www.marketwatch.com/story/becton-dickinson-to-invest-12-billion-to-expand-pre-fillable-syringe-manufacturing-capacity-for-covid-vaccination-2020-12-02
|
strategic_field
|
BDXA
|
Market Watch
|
2020-12-02 07:08:49
|
|
Minimal Dividend Growth Expected From Sysco And Becton Dickinson In Second Half Of November
|
There were no big surprises in the dividend growth announcements in the first half of November. All the usual suspects offered up payout boosts. Long time dividend growth companies Emerson and Mercury General provided token increases of 1% to keep their dividend growth streaks going.
|
https://seekingalpha.com/article/4389407-minimal-dividend-growth-expected-from-sysco-and-becton-dickinson-in-second-half-of-november
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2020-11-16 14:46:46
|
|
Becton, Dickinson And Company: Reasonable Return Prospects, With Some Caveats
|
Becton, Dickinson's reported non-GAAP earnings exclude a large amount of unusual items, some of which involve real monetary outlays. Over the last 3.75 years, dividends paid out of equity exceed the amount of income flowing into equity, if the excluded unusual items of expense are taken into account.
|
https://seekingalpha.com/article/4388555-becton-dickinson-and-company-reasonable-return-prospects-caveats
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2020-11-13 09:35:00
|
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q4 2020 Results - Earnings Call Transcript
|
Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q4 2020 Results - Earnings Call Transcript
|
https://seekingalpha.com/article/4385531-becton-dickinson-and-company-bdx-ceo-thomas-polen-on-q4-2020-results-earnings-call-transcript
|
strategic_field
|
BDXA
|
Seeking Alpha
|
2020-11-05 17:53:11
|
|
Recap: Becton, Dickinson Q4 Earnings
|
Shares of Becton, Dickinson (NYSE:BDX) were flat in pre-market trading after the company reported Q4 results.
|
https://www.benzinga.com/news/earnings/20/11/18223958/recap-becton-dickinson-q4-earnings
|
strategic_field
|
BDXA
|
Benzinga
|
2020-11-05 08:25:42
|
|
Were Hedge Funds Right About Becton, Dickinson and Company (BDX)?
|
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to Becton, Dickinson and Company (NYSE:BDX) changed recently.
|
https://www.insidermonkey.com/blog/were-hedge-funds-right-about-becton-dickinson-and-company-bdx-2-887088/
|
strategic_field
|
BDXA
|
Insider Monkey
|
2020-10-26 11:12:30
|
|
H&R Block to Release Fiscal 2023 Second Quarter Results on February 7, 2023
|
KANSAS CITY, Mo., Jan. 24, 2023 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB) will report fiscal 2023 second quarter results on Tuesday, February 7, 2023, after the New York Stock Exchange market close. At that time, a copy of the press release and presentation will be available on the company's investor relations website at https://investors.hrblock.com/.
|
https://www.globenewswire.com/news-release/2023/01/24/2594734/0/en/H-R-Block-to-Release-Fiscal-2023-Second-Quarter-Results-on-February-7-2023.html
|
strategic_field
|
HRB
|
GlobeNewsWire
|
2023-01-24 16:15:00
|
|
The 7 Best Dividend Stocks to Buy for an Uncertain 2023
|
With uncertainty baked into the possibilities for the new year, investors may want to shift their focus toward the best dividend stocks to buy. Now, don't misinterpret what I'm trying to say: it's not that you should avoid growth-oriented names altogether.
|
https://investorplace.com/2023/01/the-7-best-dividend-stocks-to-buy-for-an-uncertain-2023/
|
strategic_field
|
HRB
|
InvestorPlace
|
2023-01-23 18:56:54
|
|
7 Long-Term Stocks Every Smart Investor Should Own in 2023
|
Although the volatility of last year may tempt contrarians to go big this year, some funds should be dedicated to long-term stocks to own. Don't get me wrong – under the right circumstances, taking potshots can prove incredibly lucrative.
|
https://investorplace.com/2023/01/7-long-term-stocks-every-smart-investor-should-own-in-2023/
|
strategic_field
|
HRB
|
InvestorPlace
|
2023-01-21 13:36:37
|
|
H&R Block: Put This Recession-Resistant Stock On Your Balance Sheet
|
This article seeks to provide a valuation and pricing mechanism for H&R Block, Inc. We find a pricing mechanism for H&R Block by comparing its financial metrics to the rest of the U.S. market, assessing its financial health, and attempting to find a valuation.
|
https://seekingalpha.com/article/4571294-h-and-r-block-put-this-recession-resistant-stock-on-your-balance-sheet
|
strategic_field
|
HRB
|
Seeking Alpha
|
2023-01-20 16:03:31
|
|
The 7 Best Gig Economy Stocks to Buy for 2023
|
Not too long ago, Disney (NYSE: DIS ) dropped a bombshell, which effectively boosted the narrative of the best gig economy stocks to buy. According to a CNBC report, Disney's reappointed CEO Bob Iger requested that in March, hybrid employees will be expected to come into the office for four days of the week.
|
https://investorplace.com/2023/01/the-7-best-gig-economy-stocks-to-buy-for-2023/
|
strategic_field
|
HRB
|
InvestorPlace
|
2023-01-16 19:18:55
|
|
Reasons Why You Should Invest in H&R Block (HRB) Stock Now
|
H&R Block (HRB) is focused on using human expertise and technological infrastructure to drive innovation.
|
https://www.zacks.com/stock/news/2039714/reasons-why-you-should-invest-in-h-r-block-hrb-stock-now
|
strategic_field
|
HRB
|
Zacks Investment Research
|
2023-01-16 12:02:07
|
|
7 Oddball Stocks to Buy That Can Surprise Investors in 2023
|
If you follow the advice of legendary investor Warren Buffett literally and religiously, you might not appreciate this list of oddball stocks to buy. Chances are, at least one of these names features an area that does not meet your core area of competency.
|
https://investorplace.com/2023/01/7-oddball-stocks-to-buy-that-can-surprise-investors-in-2023/
|
strategic_field
|
HRB
|
InvestorPlace
|
2023-01-10 10:58:17
|
|
Are Investors Undervaluing H&R Block (HRB) Right Now?
|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
|
https://www.zacks.com/stock/news/2035142/are-investors-undervaluing-h-r-block-hrb-right-now
|
strategic_field
|
HRB
|
Zacks Investment Research
|
2023-01-04 11:17:31
|
|
Why H&R Block (HRB) is a Top Value Stock for the Long-Term
|
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
|
https://www.zacks.com/stock/news/2033476/why-h-r-block-hrb-is-a-top-value-stock-for-the-long-term
|
strategic_field
|
HRB
|
Zacks Investment Research
|
2022-12-29 11:17:43
|
|
5 Top-Ranked Dividend Growth Stocks for 2023
|
Archer-Daniels-Midland (ADM), Cardinal Health (CAH), Insperity (NSP), Deere & Company (DE), and H&R Block (HRB) could be compelling picks for 2023.
|
https://www.zacks.com/stock/news/2032412/5-top-ranked-dividend-growth-stocks-for-2023
|
strategic_field
|
HRB
|
Zacks Investment Research
|
2022-12-27 08:16:06
|
|
The 7 Best Short-Term Stocks to Buy Now
|
Usually, most financial advisors will direct their clients to consider the bigger picture. However, because of the unique circumstances of the post-pandemic new normal, investors may want to consider the best short-term stocks to buy.
|
https://investorplace.com/2022/12/the-7-best-short-term-stocks-to-buy-now/
|
strategic_field
|
HRB
|
InvestorPlace
|
2022-12-05 15:34:56
|
|
The 7 Best Stocks to Buy This Week
|
With the holiday-shortened sessions behind us, investors should roll up their sleeves and look for stocks to buy this week. Although the benchmark S&P 500 index remains in negative territory for the year, many market participants anticipate that the bottom is in.
|
https://investorplace.com/stocks-to-buy-this-week/
|
strategic_field
|
HRB
|
InvestorPlace
|
2022-11-28 18:32:26
|
|
7 Consumer Discretionary Stocks That Can Storm Back in 2023
|
Although the blues of 2022 negatively impacted most sectors not tethered to the energy or defense sectors, some of the top consumer discretionary stocks to buy absorbed some of the worst hits. Initially, inflation woes ground down consumer sentiment.
|
https://investorplace.com/2022/11/7-consumer-discretionary-stocks-that-can-storm-back-in-2023/
|
strategic_field
|
HRB
|
InvestorPlace
|
2022-11-28 12:58:30
|
|
H&R Block (HRB) is a Top-Ranked Value Stock: Should You Buy?
|
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
|
https://www.zacks.com/stock/news/2021845/h-r-block-hrb-is-a-top-ranked-value-stock-should-you-buy
|
strategic_field
|
HRB
|
Zacks Investment Research
|
2022-11-24 11:17:55
|
|
Final Trades: H&R Block, S&P Health Care, General Motors & more
|
The "Halftime Report" traders give their top picks to watch for the second half.
|
https://www.youtube.com/watch?v=NaLofQTWAno
|
strategic_field
|
HRB
|
CNBC Television
|
2022-11-19 02:19:00
|
|
Reasons Why You Should Invest in H&R Block (HRB) Stock Now
|
H&R Block (HRB) is focused on using human expertise and technological infrastructure to drive innovation.
|
https://www.zacks.com/stock/news/2020043/reasons-why-you-should-invest-in-h-r-block-hrb-stock-now
|
strategic_field
|
HRB
|
Zacks Investment Research
|
2022-11-18 13:41:15
|
|
Peak Inflation Seems Behind Us: 5 Consumer Discretionary Picks
|
We have narrowed our search to five consumer discretionary stocks that have strong potential for the rest of 2022. These are: H, WH, LYV, HRB and BJ.
|
https://www.zacks.com/stock/news/2018745/peak-inflation-seems-behind-us-5-consumer-discretionary-picks
|
strategic_field
|
HRB
|
Zacks Investment Research
|
2022-11-16 09:47:30
|
|
Are Consumer Discretionary Stocks Lagging H&R Block (HRB) This Year?
|
Here is how H&R Block (HRB) and Swedish Match AB Unsponsored ADR (SWMAY) have performed compared to their sector so far this year.
|
https://www.zacks.com/stock/news/2014145/are-consumer-discretionary-stocks-lagging-h-r-block-hrb-this-year
|
strategic_field
|
HRB
|
Zacks Investment Research
|
2022-11-04 11:20:38
|
|
H&R Block's (HRB) Q1 Earnings Beat Estimates, Decline Y/Y
|
H&R Block???s (HRB) first-quarter fiscal 2023 revenues fall year over year.
|
https://www.zacks.com/stock/news/2012794/h-r-block-s-hrb-q1-earnings-beat-estimates-decline-y-y
|
strategic_field
|
HRB
|
Zacks Investment Research
|
2022-11-02 14:18:27
|
|
H&R Block Inc. (HRB) Q1 2023 Earnings Call Transcript
|
H&R Block Inc. (NYSE:HRB ) Q1 2023 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Michaella Gallina - Vice President of Investor Relations Jeff Jones - President and Chief Executive Officer Tony Bowen - Chief Financial Officer Conference Call Participants Kartik Mehta - Northcoast Research George Tong - Goldman Sachs Scott Schneeberger - Oppenheimer Operator Thank you for standing by, and welcome to H&R Block's First Quarter Fiscal 2023 Results Call. At this time, all participants are in a listen-only mode.
|
https://seekingalpha.com/article/4551724-h-and-r-block-inc-hrb-q1-2023-earnings-call-transcript
|
strategic_field
|
HRB
|
Seeking Alpha
|
2022-11-01 19:11:05
|
|
The 7 Best Boring Stocks to Buy for Red-Hot Returns
|
Everyone defines “boring stocks” differently, and everyone has their own ideas about criteria for the best boring stocks. For example, I consider Mexican cement producer Cemex to be an incredibly dull stock.
|
https://investorplace.com/2022/10/the-7-best-boring-stocks-to-buy-for-red-hot-returns/
|
strategic_field
|
HRB
|
InvestorPlace
|
2022-10-31 07:49:15
|
|
New Strong Buy Stocks for October 20th
|
HQI, ABNB, SNEX, HRB and SPXC have been added to the Zacks Rank #1 (Strong Buy) List on October 20, 2022.
|
https://www.zacks.com/commentary/1993897/new-strong-buy-stocks-for-october-20th
|
strategic_field
|
HRB
|
Zacks Investment Research
|
2022-10-20 09:02:18
|
|
H&R Block to Release Fiscal 2023 First Quarter Results on November 1, 2022
|
KANSAS CITY, Mo., Oct. 18, 2022 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB) will report fiscal 2023 first quarter results on Tuesday, November 1, 2022, after the New York Stock Exchange market close. At that time, a copy of the press release and presentation will be available on the company's investor relations website at https://investors.hrblock.com/.
|
https://www.globenewswire.com/news-release/2022/10/18/2536902/0/en/H-R-Block-to-Release-Fiscal-2023-First-Quarter-Results-on-November-1-2022.html
|
strategic_field
|
HRB
|
GlobeNewsWire
|
2022-10-18 16:05:00
|
|
7 Gig Economy Stocks Set to Explode in 2023
|
With the fading of the coronavirus pandemic, the inevitable push to the office sparked fundamental interest in gig economy stocks. After enjoying the freedoms of gig life, corporate employees simply don't want to return to business as usual.
|
https://investorplace.com/2022/10/7-gig-economy-stocks-set-to-explode-in-2023/
|
strategic_field
|
HRB
|
InvestorPlace
|
2022-10-13 09:48:27
|
|
Smart Investors Will Be Buying All the Dips for These 7 Stocks
|
Although the red ink splashed on the equities sector has many bulls in the dumps, it's also important to remember that the doldrums open opportunities for these 7 stocks to buy on the dip. To be fair, you don't want to just react to volatility in a simplistic Pavlovian manner.
|
https://investorplace.com/2022/10/smart-investors-will-be-buying-all-the-dips-for-these-7-stocks/
|
strategic_field
|
HRB
|
InvestorPlace
|
2022-10-10 14:39:02
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.